Richard J. White
Chief Tech/Sci/R&D Officer at Vicuron Pharmaceuticals LLC
Profile
Richard J.
White is currently a Director at Indel Therapeutics, Inc. and previously served as the Chief Scientific Officer & EVP at Vicuron Pharmaceuticals LLC.
He was also the Vice President-Infectious Diseases at Bristol Myers Squibb Co. from 1985 to 1997.
Additionally, he served as the Chairman of F2G Ltd.
from 2010 to 2018 and held positions as a Principal at Lederle Laboratories and Glaxo Group Research Ltd.
He earned a doctorate from the University of Oxford and an undergraduate degree from The University of Manchester.
Richard J. White active positions
| Companies | Position | Start |
|---|---|---|
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | 1996-12-31 |
Indel Therapeutics, Inc.
 Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Director/Board Member | 2011-04-28 |
Former positions of Richard J. White
| Companies | Position | End |
|---|---|---|
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Chairman | 2018-11-30 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 1996-12-31 |
| Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd. | Corporate Officer/Principal | - |
| Glaxo Group Research Ltd. | Corporate Officer/Principal | - |
Lederle Laboratories
 Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Corporate Officer/Principal | - |
Training of Richard J. White
| University of Oxford | Doctorate Degree |
| The University of Manchester | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 6 |
|---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Lederle Laboratories
Lederle Laboratories Miscellaneous Commercial ServicesCommercial Services Part of Pfizer Inc., Lederle Laboratories is a company that provides testing services. The company is based in Pearl River, NY. | Commercial Services |
| Glaxo Group Research Ltd. | |
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Health Technology |
| Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd. |
- Stock Market
- Insiders
- Richard J. White
